
Latest News
See All News

NIAID Awards Contract to RxBio - National Institute for Allergy and Infectious Diseases (NIAID) awards contract to RxBio, Inc., for Accelerated Development of Radiation/Nuclear Medical Countermeasures

Rx100 Profiled in Recent Journal Publication - "Prevention and treatment of secretory diarrhea by the lysophosphatidic acid analog Rx100

RxBio CEO Dr. W. Shannon McCool is Featured on the "CEO Money" (Segments 2 & 3) Program Airing August 22, 2017, on World Finance News 1.

SBIR (NIH) Funds RxBio Work Assessing the Anti-Diarrheal Potential of an LPA analog Rx100
Milestones

Amount Awarded: $222,829
Award Period: 09/17/15 - 08/31/16
Entity: RxBio
potential of a LPA
analog Rx100

Amount Awarded: $ 297,087
Award Period: 03/01/15 - 02/29/16
Entity: RxBio
as a Novel Medical
Countermeasure for
Acute Radiation Syndrome

Amount Awarded: $6,103,776
Award Period: 09/30/13 - 04/30/17
Entity: RxBio
Countermeasures to
Mitigate or Treat
the GI-ARS after a
Nuclear or Radiation
Incident

Amount Awarded: $2,392,253
Award Period: 06/15/13 - 06/14/18
Entity: UTHSC
Preclinical Development
of a New
Radiomitigator

Amount Awarded: $15,046,191
Award Period: 09/27/11 - 03/30/14
Entity: RxBio
Rx100 as a
Parenteral Radiomitigant

Amount Awarded: $194,797
Award Period: 09/23/11 - 08/22/12
Entity: RxBio
DFMO as a
radioprotector/mitigator

Amount Awarded: $1,049,055
Award Period: 09/9/11 - 09/18/13
Entity: RxBio
Mechanism of Action
and Preclinical
Pharmacokinetic/ Pharmacodynamic
Testing in an
NHP, GI-ARS Model

Amount Awarded: $2,321,862
Award Period: 10/01/09 - 09/30/11
Entity: UTHSC
of a GI Radiation
Countermeasure

Amount Awarded: $231,011
Award Period: 07/22/09 - 02/28/10
Entity: RxBio
Efficacy of Rx100
in the
Gastrointestinal Tract

Amount Awarded: $449,896
Award Period: 07/01/09 - 02/28/11
Entity: UTHSC
Novel GI Radiomitigator

Amount Awarded: $106,670
Award Period: 05/01/09 - 04/30/10
Entity: UTHSC
Novel Gastrointestinal
Radiomitigator

Amount Awarded: $248,548
Award Period: 08/01/08 - 07/31/10
Entity: UTHSC
and OTP promotes
wound healing in
a radiation
combined injury

Amount Awarded: $168,560
Award Period: 08/01/08 - 07/31/10
Entity: UTHSC
and OTP promotes
wound healing
in a radiation
combined injury

Amount Awarded: $10,167
Award Period: 08/01/08 - 07/31/10
Entity: UTHSC
and OTP promotes
wound healing in
a radiation combined
injury

Amount Awarded: $371,393
Award Period: 07/08/08 - 06/30/13
Entity: UTHSC
Radiomitigative
Cell Signaling

Amount Awarded: $346,086
Award Period: 07/08/08 - 06/30/13
Entity: UTHSC
Signaling through
the GPCR-PPARgamma
Axis

Amount Awarded: $99,999
Award Period: 06/27/08 - 11/30/08
Entity: RxBio
receptor modulator
Rx100 as a
radioprotectant

Amount Awarded: $1,000,000
Award Period: 09/01/07 - 02/28/11
Entity: UTHSC
Novel GI Radiomitigator

Amount Awarded: $499,999
Award Period: 09/01/07 - 03/01/09
Entity: RxBio
Efficacy of Rx100 in
the Gastrointestinal Tract

Amount Awarded: $97,162
Award Period: 08/01/07 - 01/30/08
Entity: RxBio
Modulators as
Radioprotectants

Amount Awarded: $285,763
Award Period: 08/01/01 - 07/31/11
Entity: UTHSC
by Phospholipid
Growth Factor
Receptors

Amount Awarded: $285,624
Award Period: 08/01/01 - 07/31/11
Entity: UTHSC
by Phospholipid
Growth Factor
Receptors
More News


NIAID Funds Tigyi (UTHSC) Work for IND-Enabling Preclinical Development of a New RxBio Radiomitigator

McCool, RxBio Holdings team pursuing a second promising drug. Read more...

RxBio’s Shannon McCool following a non-traditional commercialization path. Read more...